Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

6.9K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Splicing-associated network PAK1-CLK1/4-SRRM1 is a vulnerability to overcome chemoresistance in human and mouse acute myeloid leukemia.

Science translational medicine·2026
Same author

Met-Vision reveals coexisting energetic states in tissue macrophages redistributed by inflammation.

The Journal of cell biology·2026
Same author

Lymph node fine-tuning FcγR signaling boosts anti-PD-1 therapy.

Journal for immunotherapy of cancer·2026
Same author

Lymph node microenvironment remodeling unlocks local antibody-mediated B cell depletion.

Science advances·2026
Same author

Mutation-dependent responses to sleep and exercise in clonal haematopoiesis.

Nature·2026
Same author

CAR-T cells targeting fibroblast activation protein eliminate pathological fibroblasts and preserve cardiac function in a Duchenne Muscular Dystrophy murine model.

Stem cell research & therapy·2026

Related Experiment Video

Updated: Sep 11, 2025

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes
10:03

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

9.9K

Reprogramming RIPK3-induced cell death in malignant B cells promotes immune-mediated tumor control.

Ruby Alonso1, Zacarias Garcia1, Béatrice Corre1

  • 1Dynamics of Immune Responses Unit, Institut Pasteur, Université de Paris Cité, INSERM U1223, F-75015 Paris, France.

Science Advances
|August 15, 2025
PubMed
Summary

Researchers found a new way to fight B cell cancers by reprogramming Receptor-interacting serine/threonine protein kinase 3 (RIPK3) signaling. This strategy enhances immune responses against tumors, offering a promising new therapeutic avenue.

More Related Videos

Retroviral Overexpression of CXCR4 on Murine B-1a Cells and Adoptive Transfer for Targeted B-1a Cell Migration to the Bone Marrow and IgM Production
08:22

Retroviral Overexpression of CXCR4 on Murine B-1a Cells and Adoptive Transfer for Targeted B-1a Cell Migration to the Bone Marrow and IgM Production

Published on: May 31, 2020

5.2K
Tyramide Signal Amplification for the Immunofluorescent Staining of ZBP1-Dependent Phosphorylation of RIPK3 and MLKL After HSV-1 Infection in Human Cells
09:15

Tyramide Signal Amplification for the Immunofluorescent Staining of ZBP1-Dependent Phosphorylation of RIPK3 and MLKL After HSV-1 Infection in Human Cells

Published on: October 20, 2022

2.4K

Related Experiment Videos

Last Updated: Sep 11, 2025

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes
10:03

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

9.9K
Retroviral Overexpression of CXCR4 on Murine B-1a Cells and Adoptive Transfer for Targeted B-1a Cell Migration to the Bone Marrow and IgM Production
08:22

Retroviral Overexpression of CXCR4 on Murine B-1a Cells and Adoptive Transfer for Targeted B-1a Cell Migration to the Bone Marrow and IgM Production

Published on: May 31, 2020

5.2K
Tyramide Signal Amplification for the Immunofluorescent Staining of ZBP1-Dependent Phosphorylation of RIPK3 and MLKL After HSV-1 Infection in Human Cells
09:15

Tyramide Signal Amplification for the Immunofluorescent Staining of ZBP1-Dependent Phosphorylation of RIPK3 and MLKL After HSV-1 Infection in Human Cells

Published on: October 20, 2022

2.4K

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • Immunogenic cell death, including necroptosis, can enhance anti-tumor immune responses.
  • Receptor-interacting serine/threonine protein kinase 3 (RIPK3) signaling is crucial for necroptosis and immune activation in solid tumors.
  • The therapeutic potential of RIPK3 manipulation in B cell malignancies is largely unexplored.

Purpose of the Study:

  • To investigate the role of RIPK3 signaling in B cell malignancies.
  • To develop a strategy for manipulating RIPK3 activity to promote immune-mediated tumor control in B cell cancers.

Main Methods:

  • Utilized intravital imaging to monitor and control RIPK3 signaling in malignant B cells.
  • Investigated RIPK3-induced cell death pathways, including apoptosis and necroptosis.
  • Employed combination therapy involving RIPK3 activation, caspase inhibition, and type I interferon.

Main Results:

  • RIPK3 activation in B cells induced apoptosis and macrophage engulfment but not necroptosis due to low MLKL expression.
  • Co-treatment with type I interferon and caspase inhibitors successfully redirected RIPK3-induced cell death towards necroptosis.
  • The combination therapy demonstrated significant immune-mediated control of B cell tumors.

Conclusions:

  • Reprogramming RIPK3 activity is a viable strategy for targeting B cell malignancies.
  • Combination therapy modulating RIPK3 signaling offers a promising approach for enhancing anti-tumor immunity in B cell cancers.